Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Christof Vulsteke, MD, PhD
Advertisement
Christof Vulsteke, MD, PhD, is head of Integrated Cancer Center Ghent (IKG, Belgium) and Clinical Trial Unit Oncology Ghent.
Articles by Christof Vulsteke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
5
